Machine learning and QSP offer new tools for rare disease research
A new perspective published in CPT: Pharmacometrics & Systems Pharmacology highlights how the integration of machine learning (ML), quantitative systems pharmacology (QSP), and hybrid modeling can accelerate drug development for pediatric rare diseases.
Developed through the collaboration between InSilicoTrials, COSBI, and Axoltis Pharma, the article showcases how virtual patient technologies can support dose optimization, disease modeling, and innovative trial design—bringing new opportunities to an area of high unmet medical need.
Read the full article
